Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2017 > Volume 26 Number 4 July 2017 > AORTIC VALVE DISEASE > Long-Term Outcomes in Patients Undergoing Consecutive Bioprosthetic Aortic Valve Replacement

Long-Term Outcomes in Patients Undergoing Consecutive Bioprosthetic Aortic Valve Replacement

Matthew D. Haydock1,2,3, Carissa F. Wilkes2, Tharumenthiran Ramanathan1, David A. Haydock1

1Green Lane Cardiothoracic Surgical Unit, Auckland City Hospital, New Zealand
2The University of Auckland, Department of Surgery, Auckland, New Zealand
3Electronic correspondence: mhaydock@adhb.govt.nz

Background and aim of the study: Worldwide, there is increased use of bioprosthetic valves in the aortic position. Part of this increase has been patient-driven for quality of life reasons. More recently, bioprosthetic valves have been chosen by progressively younger patients, with a strategy of performing a valve-in-valve TAVI if the prosthesis should wear out. Thus, a review was undertaken of the present authors’ experience with patients whose first two aortic valve replacements (AVRs) were with bioprosthetic valves.

Methods: Patients receiving consecutive bioprosthetic AVRs at the Green Lane Cardiothoracic Surgical Unit were identified from a departmental database. Data were retrieved from prospective databases, electronic and archived clinical records. Outcomes of interest were overall survival and freedom from a third or more AVR.

Results: A total of 267 patients met the inclusion criteria, with a mean follow up of 22.3 years. Concurrent procedures (e.g., coronary artery bypass grafting) were performed in 65.2% of patients that underwent two

bioprosthetic AVRs, and in 79.8% of patients undergoing three or more bioprosthetic AVRs. Median survival of the cohort was 31.7 years. Age at operation was the best predictor of needing a third or more AVR. Receiver operating characteristic curve analysis identified that age <45 years at the first operation and <56 years at the second operation were the optimal cut-off point for the likelihood of needing a third or more aortic valve intervention.

Conclusion: Overall survival for consecutive bioprosthetic AVRs was remarkably good. Data relating to consecutive bioprosthetic AVRs is of particular interest in the context of TAVI and valve-in-valve TAVI, which will likely significantly increase the number of patients receiving consecutive bioprosthetic valves. However, it must be noted that the majority of patients in this cohort required concurrent cardiac surgical procedures. The study results provided encouraging data for consecutive bioprosthetic AVRs, as well as data that may be of interest in the setting of TAVI being performed in younger cohorts of patients.

The Journal of Heart Valve Disease 2017;26:423-429


Long-Term Outcomes in Patients Undergoing Consecutive Bioprosthetic Aortic Valve Replacement

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.